Orgenesis Inc. ORGS · Stock Open Orgenesis Inc. in new tab
Orgenesis Inc. Analysis (ORGS)
Is Orgenesis Inc. a good investment? Orgenesis Inc. (ORGS) is currently trading at 0.2500 USD.
Earnings Schedule: Orgenesis Inc. is expected to release its next earnings report on Aug. 7, 2026. The market consensus estimate for Forward EPS is 0.61.
Investor FAQ
Does Orgenesis Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Orgenesis Inc.?
Orgenesis Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Aug. 7, 2026. The company currently has a trailing EPS of -11.44.
Company Profile
Orgenesis Inc., a biotech company, focuses on cell and gene therapies in the United States. It operates through two segments: Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare model, POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. It also provides hospital services and cell process development services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.
| Split Date | Split Ratio to 1 |
|---|---|
| Nov. 16, 2017 | 0.080000 |
| Sept. 25, 2024 | 0.100000 |
Community Discussion